BY SEAN WHOOLEY
(Mass Device) — Extracardiac temporary pacing technology developer AtaCor Medical announced today that it completed a $25 million Series B financing round.
Existing investors Broadview Ventures and aMoon Fund led San Clemente, Calif.-based AtaCor’s funding round, while new investors Hatteras Venture Partners, Catalyst Health Ventures and Longview Ventures contributed. Hatteras partner Jeff Terrell and Catalyst Health Ventures managing partner Darshana Zaveri will also join AtaCor’s board of directors.
AtaCor said in a news release that the investment is earmarked for efforts to garner U.S. and European regulatory clearances for its novel extracardiac temporary pacing system, while it may also be used to fund development efforts for additional extracardiac therapies.